Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

4.540 -0.255 (-5.31%)

Delayed Quote Updated: 1:37 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	27,885
Open	4.850
Bid (Size)	4.520 (100)
Ask (Size)	4.710 (200)
Prev. Close	4.795
Today's Range	4.540 - 4.850
52wk Range	3.280 - 9.821
Shares Outstanding	41,957,197
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

September 30, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

September 10, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Performance

YTD	-45.3%	-45.3%
1 Month	-16.8%	-16.8%
3 Month	-23.6%	-23.6%
6 Month	-17.3%	-17.3%
1 Year	+5.3%	+5.3%

More News

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 08, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica (VRCA) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum ↗

May 12, 2026

Via Chartmill

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) Reports Q4 Earnings Beat and Accelerating Revenue Growth ↗

March 11, 2026

Via Chartmill

Verrica Pharmaceuticals Q2 Earnings Call Highlights ↗

August 07, 2026

Via MarketBeat

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 06, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 06, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

June 22, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica (VRCA) Q1 2026 Earnings Transcript ↗

May 13, 2026

Via The Motley Fool

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 13, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Q1 Earnings Call Highlights ↗

May 12, 2026

Via MarketBeat

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

May 12, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

May 05, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

May 05, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

April 09, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 06, 2026

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm

March 20, 2026

From The Schall Law Firm

Via Business Wire

VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

March 20, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA

March 19, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

Frequently Asked Questions

Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?

Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?

The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market

What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?

The current price of Verrica Pharmaceuticals Inc. - Common Stock is 4.540

When was Verrica Pharmaceuticals Inc. - Common Stock last traded?

The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 10/01/26 01:37 PM ET

What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?

The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 190.49M

How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?

Verrica Pharmaceuticals Inc. - Common Stock has 190M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.